RxDoctor Payments DataLook up a doctor →

Ricardo Velazquez, MD

Internal Medicine · Las Vegas, NVNPI 1831278928

Payments from drug & device makers

$11,125in general payments, 2019–2025

Across 512 payments — averaging $21.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • AbbVie$2K
  • Novo Nordisk$814
  • Boehringer Ingelheim$560
  • GSK$535
  • Lilly USA, LLC$535
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$11,04199%
  • Education$841%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,125 in reported general payments places this provider in the 90th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$240,199
Medicare patients
185
Services billed
2,355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol106$131,920
TrulicityDulaglutide61$84,103
JardianceEmpagliflozin37$53,388
EliquisApixaban26$35,361
OzempicSemaglutide28$33,435
Trijardy XrEmpaglifloz/Linaglip/Metformin22$28,357
VraylarCariprazine Hcl11$28,083
LinzessLinaclotide23$23,510
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$19,349
JanuviaSitagliptin Phosphate13$16,658
GlyxambiEmpagliflozin/Linagliptin12$16,606
MounjaroTirzepatide13$14,489
Tresiba Flextouch U-200Insulin Degludec23$13,981
SymbicortBudesonide/Formoterol Fumarate32$11,916
Stiolto RespimatTiotropium Br/Olodaterol Hcl20$9,795

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$3,639$163,184167 claims
Boehringer IngelheimJardiance, Trijardy Xr, Glyxambi, Stiolto Respimat$560$108,14691 claims
Lilly USA, LLCTrulicity, Mounjaro$535$98,59274 claims
AbbVieVraylar, Linzess$1,661$51,59334 claims
PfizerEliquis$333$35,36126 claims
Novo NordiskOzempic$814$33,43528 claims
MerckJanuvia$412$16,65813 claims
GSKAnoro Ellipta$535$6,30412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →